Proactive Research analyst John Savin presents his research Tiziana Life Sciences which uses its delivery technology to administer its fully human therapeutic anti-CD3 antibody, foralumab, to mucosal surfaces in the nose or gut; antibodies are usually injected or infused giving Tiziana a novel market position.
Foralumab potentially modulates the immune system, so it could be used to treat various autoimmune diseases. A key project in Multiple Sclerosis (MS) has reported fresh data, highlighted on a key opinion leader (KOL) call. A progressive secondary MS patient using nasal foralumab for six months showed signs of disease retardation and is continuing treatment. A second patient started therapy in January 2022.